Synairgen plc (LON:SNG)‘s stock had its “corporate” rating reiterated by FinnCap in a research note issued to investors on Wednesday. They currently have a GBX 137 ($1.70) price target on the stock. FinnCap’s price target suggests a potential upside of 302.94% from the company’s current price.
Separately, N+1 Singer reduced their price objective on Synairgen plc from GBX 47 ($0.58) to GBX 46 ($0.57) and set a “buy” rating on the stock in a research report on Thursday, September 22nd.
Shares of Synairgen plc (LON:SNG) opened at 34.00 on Wednesday. Synairgen plc has a 12-month low of GBX 19.00 and a 12-month high of GBX 38.00. The company’s market cap is GBX 31.06 million. The stock’s 50 day moving average price is GBX 33.73 and its 200 day moving average price is GBX 31.25.
Synairgen plc Company Profile
Synairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls).
Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with MarketBeat.com's FREE daily email newsletter.